NCT02183246终止3 期
A Phase III, Double-Blind, Randomized, Placebo-Controlled Study of Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 3
- 主要终点
- Time to Disease Progression
研究概览
简要总结
Determination of efficacy and safety of porfiromycin versus placebo as an adjuvant to radiotherapy in postoperative head and neck a cancer patients as well as assessment of population pharmacokinetic parameters.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female postoperative radical neck surgery patients with histologically proven Stage III or IV (without distant metastases) epidermoid (squamous cell) carcinoma of the head and neck limited to the following locations as defined by the American Joint Commission (AJC): lip and oral cavity, pharynx, or larynx.
- •Postoperative radical patients whose specimen had a) microscopic positive tumor cell margins (< 2mm from surgical margin) or b) extranodal capsular spread (perineural-vascular embolization) or c) two or more positive nodes
- •Postoperative radical neck patients must have received Radiotherapy (RT).
- •Performance status of ≥ 70 on the Karnofsky Performance Score (KPS) at screening.
- •Patients ≥ 18 years of age
- •Patients must have provided written informed consent prior to participation in the trial.
- •Patients must have demonstrated an educational level and a degree of understanding such that they could communicate effectively with the investigator.
排除标准
- •Patients that received any prior chemotherapy including mitomycin-C or porfiromycin.
- •Treatment with granulocyte, granulocyte-macrophage stimulating factor (G-CSF, GM-CSF) or Interleukin-11 within 30 days prior to start of RT.
- •RT within the treatment field for any malignancy within the past five years.
- •Patients who had any gross (visible or palpable) residual disease left after surgery.
- •Patients who met any of the following clinical laboratory criteria upon screening:
- •Granulocyte (neutrophil) count of < 1,500/cubic millimeters (mm3)
- •Platelets < 75,000/mm3
- •Prothrombin time (PT) and partial thromboplastin time (PTT) > 1.5 times the upper limit of normal (ULN) in seconds.
- •Women who were pregnant or nursing.
- •Women of childbearing potential who were unwilling to utilise a medically acceptable method of contraception (oral contraceptives, intrauterine devices, diaphragm or subdermal implants eg: Norplant®).
- •Other malignancies active within the past five years (other than basal or squamous cell carcinomas of the skin outside the planned radiation portals, or in situ carcinoma of the cervix).
- •The presence of more than one primary tumor or presence of distant metastases.
- •The presence of any other life-threatening illness, such a severe chronic lung, liver, or heart disease that would be expected to be fatal within five years, regardless of the patient's cancer status.
- •Patients who participated in a clinical trial with another investigational drug or treatment 30 days prior to screening.
研究组 & 干预措施
Porfiromycin + Radiotherapy
Experimental
干预措施: Porfiromycin (Drug)
Porfiromycin + Radiotherapy
Experimental
干预措施: Radiotherapy (Radiation)
Placebo + Radiotherapy
Placebo Comparator
干预措施: Placebo (Drug)
Placebo + Radiotherapy
Placebo Comparator
干预措施: Radiotherapy (Radiation)
结局指标
主要结局
Time to Disease Progression
时间窗: week 4 and 8 post treatment, every 8 weeks until end of study
Serum porfiromycin concentration-time profile
时间窗: up to week 7
Maximum toxicity grades of Adverse Events (AE)
时间窗: until 42 days after end of treatment
Time to non-accidental death
时间窗: week 4 and 8 post treatment, every 8 weeks until end of study
次要结局
- Loss of local or regional control or distant metastasis(4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study)
- Death for any reason(4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study)
- Loss of local or regional control, distant metastasis or death for any reason(4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study)
- Significant changes in laboratory tests(up to week 7)
- Loss of local or regional control(4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study)
- Occurrence of Adverse Events(up to week 16)
- Changes from baseline in Patients health related Quality of life-Questionnaires(week 1, 5, 7, 4 weeks post treatment, every 12 weeks until end of study)
研究者
相似试验
招募中
3 期
Adujvant CT+CRT vs Adujvant CT After D2 Resection for Locally Advanced Proximal Gastric AdenocarcinomaGastric AdenocarcinomaNCT03973008Zhejiang Cancer Hospital408
终止
3 期
A Phase III Study of Radiotherapy With or Without Adjuvant C/T in Advanced Stage Nasopharyngeal Carcinoma PatientsNasopharyngeal CarcinomaNCT00201344National Health Research Institutes, Taiwan320
进行中（未招募）
不适用
Phase I/II-StudiePraeoperative Radiochemotherapie mit Capecitabin plus Oxaliplatin und Cetuximab beim lokal fortgeschrittenen Rektumkarzinom im UICC-Stadium II und III - Cetcapox-RTRektumkarzinomEUCTR2004-002803-34-DEKlinik und Poliklinik fuer Strahlentherapie, Universität Erlangen-Nürnberg
已完成
3 期
Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal MelanomaUveal MelanomaNCT02843386Institut Curie302
招募中
3 期
Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPCQuality of LifeThyroid DiseasesRadiotherapy Side EffectRadiotherapyNasopharyngeal CarcinomaNCT06752239Jiangxi Provincial Cancer Hospital474